Tonix Pharmaceuticals Holding (TNXP) Gross Margin (2023 - 2025)
Historic Gross Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to 58.45%.
- Tonix Pharmaceuticals Holding's Gross Margin rose 135500.0% to 58.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.31%, marking a year-over-year increase of 135700.0%. This contributed to the annual value of 23.07% for FY2024, which is 158900.0% down from last year.
- Latest data reveals that Tonix Pharmaceuticals Holding reported Gross Margin of 58.45% as of Q3 2025, which was up 135500.0% from 63.76% recorded in Q2 2025.
- In the past 5 years, Tonix Pharmaceuticals Holding's Gross Margin ranged from a high of 61.18% in Q1 2025 and a low of 63.76% during Q2 2025
- Its 3-year average for Gross Margin is 23.71%, with a median of 40.49% in 2023.
- The largest annual percentage gain for Tonix Pharmaceuticals Holding's Gross Margin in the last 5 years was 280600bps (2025), contrasted with its biggest fall of -112700bps (2025).
- Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Gross Margin stood at 37.36% in 2023, then surged by 45bps to 54.18% in 2024, then increased by 8bps to 58.45% in 2025.
- Its Gross Margin stands at 58.45% for Q3 2025, versus 63.76% for Q2 2025 and 61.18% for Q1 2025.